Premium
Private equity firm Carlyle has trimmed its stake in Indegene, just two years after teaming up with another investment firm to joint betting $200 million (Rs 1,500 crore then) on the healthtech venture. Carlyle had joined hands with Brighton Park Capital, a private investment firm that focuses on software, information services, ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
